1. University of Oregon and mAbDx finalize a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products

    Thu 28 June 2012

    The University of Oregon and mAbDx have finalized a License Agreement to develop and commercialize CTIP2 immunoassays as in vitro Diagnostic Licensed Products.  CTIP2 (also known as BCL11b) is a zinc finger transcription factor essential for transcriptional control of hundreds of genes encoding key proteins in cell signaling pathways during …

    read more
  2. mAbDx and MitoSciences/Abcam sign Master Project Agreement

    Tue 17 January 2012

    mAbDx and MitoSciences/Abcam sign Master Project Agreement for mAbDx to develop medical/clinical diagnostics for:  1) sepsis, 2) SIRS (Systemic Inflammatory Response Syndrome), 3) HNSCC (Head and Neck Squamous Cell Carcinoma), 4) preeclampsia, and 5) inherited diseases affecting mitochondrial OXPHOS complexes I and IV.

    read more

« Page 4 / 5 »